Open access
Open access
Powered by Google Translator Translator

Coronary Insufficiency

2023 Guidelines on the diagnosis and management of chronic coronary syndrome

25 Jan, 2023 | 11:25h | UTC

2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome – Acta Cardiologica Sinica

Related: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology

 

Retrospective Study | Serial troponin-T and long-term outcomes in suspected acute coronary syndrome

24 Jan, 2023 | 14:09h | UTC

Serial troponin-T and long-term outcomes in suspected acute coronary syndrome – European Heart Journal

 

Commentary on Twitter

 

Review | Wellens syndrome: an important consideration in patients with chest pain

23 Jan, 2023 | 13:26h | UTC

Wellens syndrome: An important consideration in patients with chest pain – JAAPA

Commentary: Wellens Syndrome Important to Consider if Chest Pain: Key Points – American College of Cardiology

 

SR | Comparison of various calcium antagonists on vasospastic angina

18 Jan, 2023 | 14:16h | UTC

Comparison of various calcium antagonist on vasospastic angina: a systematic review – openheart

 

The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischemic heart disease

9 Jan, 2023 | 14:28h | UTC

The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischaemic heart disease – European Heart Journal

 

Commentary on Twitter

 

AHA Scientific Statement | Management of acute coronary syndrome in the older adult population.

13 Dec, 2022 | 14:35h | UTC

Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association – Circulation

News Release: Hearts and bodies change with age, heart disease treatments may need to change, too – American Heart Association

Top Things to Know: Management of ACS in the Older Adult Population – American Heart Association

Commentaries: 

The Management of ACS in Older Patients: Is Age Just a Number? – American Heart Association

Cardiovascular Aging and Acute Coronary Syndromes: Unique Challenges and Solutions for Our Elderly Patients – American Heart Association

 

RCT | Utility of coronary CT angiography for patients with suspected acute coronary syndrome.

9 Dec, 2022 | 13:22h | UTC

Prospective RandOmised Trial of Emergency Cardiac Computerised Tomography (PROTECCT) – Heart

 

Commentary on Twitter

 

Under a http://creativecommons.org/licenses/by-nc/4.0/ License

 

Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.

23 Nov, 2022 | 14:02h | UTC

Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease – Journal of the American College of Cardiology

Editorial: HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity? – Journal of the American College of Cardiology

News Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health

Commentary: Study suggests that HDL or ‘good’ cholesterol is less beneficial than previously thought, especially for Black adults – CNN

 

RCT | Clopidogrel is better than Aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

17 Nov, 2022 | 12:30h | UTC

Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study – Circulation

Related: 

Meta-analysis of randomized trials: Clopidogrel is better than aspirin for the secondary prevention of cardiovascular events.

#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

 

Commentary on Twitter

https://twitter.com/CircAHA/status/1589647384073703426 

 

RCT | Bivalirudin is superior to heparin in patients with ST-segment elevation myocardial infarction undergoing primary PCI.

15 Nov, 2022 | 13:00h | UTC

Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial – The Lancet

Commentaries:

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI – TCTMD

Bivalirudin found to be safer and more effective than heparin for treating heart attack patients undergoing percutaneous coronary intervention – Mount Sinai School of Medicine

BivaliRudin with prolonged full-dose Infusion during primary PCI versus Heparin Trial – BRIGHT-4 – American College of Cardiology

 

RCT | Indobufen vs. aspirin on top of clopidogrel after coronary drug-eluting stent implantation.

11 Nov, 2022 | 14:03h | UTC

Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial – Circulation

 

Commentary on Twitter

 

On the natural history of coronary artery disease: a longitudinal nationwide serial angiography study.

10 Nov, 2022 | 14:03h | UTC

On the Natural History of Coronary Artery Disease: A Longitudinal Nationwide Serial Angiography Study – Journal of the American Heart Association

 

Study Commentary | Radial artery beats both right internal thoracic artery and vein grafting at 15 years.

9 Nov, 2022 | 12:28h | UTC

(Not published yet, presented at the American Heart Association Scientific Sessions, November 6, 2022)

RAPCO: Radial Artery Beats Both RITA and Vein Grafting at 15 Years – TCTMD

See also:

Radial Artery Patency and Clinical Outcomes Study–Right Internal Thoracic Artery – RAPCO-RITA – American College of Cardiology

Radial Artery Patency and Clinical Outcomes Study–Saphenous Vein – RAPCO-SV – American College of Cardiology

Related:

Meta-analysis: Radial artery graft vs. saphenous vein graft in long-term cardiovascular outcomes among patients undergoing coronary artery bypass grafting

Meta-Analysis: Radial-Artery vs Saphenous-Vein Grafts in CABG

 

M-A | Comparative efficacy of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after PCI.

9 Nov, 2022 | 12:20h | UTC

Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials – Frontiers in Pharmacology

 

Follow-up of the ISCHEMIA trial | Similar survival after invasive vs. conservative management of stable coronary disease.

8 Nov, 2022 | 12:32h | UTC

Survival After Invasive or Conservative Management of Stable Coronary Disease – Circulation (free for a limited period)

Original Articles:

ISCHEMIA Trial: Health-Status Outcomes with Initial Invasive vs. Conservative Care in Stable Coronary Disease

ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease

ISCHEMIA Trial: Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease

ISCHEMIA Trial: Management of Coronary Disease in Patients with Advanced Kidney Disease

See also:

RCT | In patients with severe ischemic left ventricular systolic dysfunction under optimal medical therapy, revascularization by PCI did not improve outcomes.

 

Commentary on Twitter

 

M-A | Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention.

1 Nov, 2022 | 12:14h | UTC

Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials – BMC Cardiovascular Disorders

 

Commentary on Twitter

Under a http://creativecommons.org/licenses/by/4.0/ license

 

Cohort Study | Pre-eclampsia is associated with increased risk of premature-onset obstructive coronary artery stenosis.

1 Nov, 2022 | 12:02h | UTC

Severity of obstructive coronary artery stenosis after pre-eclampsia – Heart

Related:

Primary Care–Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review – Journal of General Internal Medicine

Pregnancy Complications and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study – Journal of the American Heart Association

AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk

Consensus statement: Cardiovascular health after menopause transition, pregnancy disorders, and other gynecologic conditions

Cohort Study: Preeclampsia and Cardiovascular Disease

Cohort Study: Cardiovascular Disease After Hypertensive Disorders of Pregnancy Largely Explained by Conventional Cardiovascular Risk Factors

All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease

Gestational Hypertension and Future Risk of Cardiovascular Disease

Research: Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents

 

New horizons in Type 2 myocardial infarction: pathogenesis, assessment and management of an emerging geriatric disease.

26 Oct, 2022 | 14:27h | UTC

New horizons in Type 2 myocardial infarction: pathogenesis, assessment and management of an emerging geriatric disease – Age and Ageing

 

M-A | Coronary perforation incidence, outcomes and temporal trends.

24 Oct, 2022 | 14:10h | UTC

Coronary perforation incidence, outcomes and temporal trends (COPIT): a systematic review and meta-analysis – openheart

 

M-A | The optimal timing for non-culprit PCI in patients with multivessel coronary artery disease.

21 Oct, 2022 | 12:52h | UTC

The optimal timing for non-culprit percutaneous coronary intervention in patients with multivessel coronary artery disease: A pairwise and network meta-analysis of randomized trials – Frontiers in Cardiovascular Medicine

 

Cohort Study | 3-year outcomes of patients with spontaneous coronary artery dissection.

19 Oct, 2022 | 14:23h | UTC

Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Spontaneous Coronary Artery Dissection: Lower Than Expected Recurrence Rate in a Large Prospective Canadian Cohort – Journal of the American College of Cardiology

Commentary: SCAD Heart Attacks: Outcomes Not as Bad as Previously Feared – Daytonews

 

Position Statement | Use of biomarkers for the management of heart failure and acute coronary syndrome.

17 Oct, 2022 | 12:34h | UTC

Saudi Heart Association Position Statement on the Use of Biomarkers for the Management of Heart Failure and Acute Coronary Syndrome – Journal of the Saudi Heart Association

 

RCT | Allopurinol does not improve outcomes in patients with ischemic heart disease without previous gout.

13 Oct, 2022 | 13:53h | UTC

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Invited Commentary: Xanthine oxidase inhibition for cardiovascular disease prevention – The Lancet

Related: [News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.

 

Commentary on Twitter

Under a Creative Commons Attribution (CC BY 4.0) License

 

Review | Therapeutic management of anomalous coronary arteries originating from the opposite sinus of Valsalva.

11 Oct, 2022 | 13:32h | UTC

Therapeutic Management of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva: Current Evidence, Proposed Approach, and the Unknowing – Journal of the American Heart Association

 

Commentary from the author on Twitter

Under a Creative Commons Attribution‐NonCommercial License

 

M-A of randomized trials | Colchicine and coronary heart disease risks.

3 Oct, 2022 | 14:00h | UTC

Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials – Frontiers in Cardiovascular Medicine

Related:

M-A: Colchicine after percutaneous coronary intervention significantly reduces the risk of major adverse cardiovascular events in patients with symptomatic coronary artery disease.

Expert Analysis | Colchicine in acute coronary syndrome: when to commence?

M-A: Colchicine in patients with coronary artery disease – “colchicine reduces the risk of myocardial infarction and stroke, but has a higher rate of gastrointestinal upset with no influence on all‐cause mortality”.

Review: Colchicine and the heart.

M-A: Colchicine administration for percutaneous coronary intervention

M-A: Efficacy and safety of low-dose colchicine in patients with coronary disease

Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease

Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease

#ESCCongress – [Abstract Only] Randomized trial: Colchicine in patients with chronic coronary disease

#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome

#ESCCongress – Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

#AHA19 – [Abstract Only] Practice Changing? – Randomized Trial: Low-Dose Colchicine Improves Outcomes after Myocardial Infarction

Research: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome

 

Stay Updated in Your Specialty

No spam, just news.